Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys, Alamar Biosciences Ink Pact for Plasma Proteome Research

NEW YORK – Proteomics firms Alamar Biosciences and Biognosys announced Thursday a partnership around the discovery of protein biomarkers in biofluids.

Under the collaboration, the companies will bring together Zurich-based Biognosys' mass spectrometry expertise with Freemont, California-based Alamar's high-sensitivity immunoassays, combining deep unbiased discovery data with more targeted analysis of low abundance proteins like cytokines, chemokines, and certain disease markers.

Financial and other terms of the agreement were not disclosed.

Biognosys will offer Alamar's NULISA assays out of its Switzerland-based facility. The companies will also enter a joint research effort exploring plasma biology through deep coverage of the plasma proteome.

At the upcoming American Society for Cancer Research (AACR) 2024 Annual Meeting, Alamar will present data from a collaborative study undertaken by the companies in which they used their platforms to analyze plasma samples from a cohort of non-small cell lung cancer patients.

"Our combined efforts will pave the way for breakthroughs in plasma biology by analyzing in an unbiased way more than 5,000 proteins together with panels of hundreds of well-characterized cytokines and other high-value, low-abundance proteins using highly specific NULISA assays," Biognosys Founder and CEO Oliver Rinner said in a statement. "With this approach we are aiming to cover the whole dynamic range of plasma proteins."

"We are thrilled to partner with Biognosys to provide the research community with expanded access to proteomic insights from discovery through to clinical research," Yuling Luo, chairman, founder and CEO of Alamar, said in a statement. "Biognosys is a leading provider of advanced mass spec proteomics services to researchers around the world, and we look forward to adding the highest sensitivity high-multiplex immunoassays to their plasma proteomics offering."